Csenge Advisory Group Has $563,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Csenge Advisory Group lifted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 21.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,767 shares of the biotechnology company’s stock after purchasing an additional 310 shares during the quarter. Csenge Advisory Group’s holdings in United Therapeutics were worth $563,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rise Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC purchased a new stake in United Therapeutics in the 4th quarter worth about $43,000. Benjamin F. Edwards & Company Inc. lifted its stake in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. Janiczek Wealth Management LLC lifted its stake in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Covestor Ltd lifted its stake in United Therapeutics by 83.1% in the 1st quarter. Covestor Ltd now owns 509 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 231 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on UTHR shares. UBS Group increased their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Wells Fargo & Company raised their price target on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Oppenheimer raised their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $331.73.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Friday, July 26th. The stock was sold at an average price of $338.61, for a total value of $1,218,996.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher Patusky sold 1,310 shares of United Therapeutics stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Insiders sold 128,644 shares of company stock worth $39,863,643 in the last 90 days. 12.50% of the stock is owned by company insiders.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $8.81 during trading on Thursday, hitting $331.04. 333,837 shares of the stock were exchanged, compared to its average volume of 494,138. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $343.98. The company has a market capitalization of $14.73 billion, a price-to-earnings ratio of 15.65, a price-to-earnings-growth ratio of 1.17 and a beta of 0.55. The company’s fifty day simple moving average is $312.75 and its 200-day simple moving average is $263.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the business posted $5.24 EPS. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 24.79 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.